UPDATE: JPMorgan Downgrades Idera Pharmaceuticals (IDRA) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Wall St gains on bright earnings, megacaps' support
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil falls back after robust EU data as Mideast tensions linger
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- Apple, PepsiCo, JetBlue fall premarket; Amazon, GM and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
Idera Pharma (IDRA) call put ratio 1 call to 2.2 puts into announces ILLUMINATE-301 trial misses primary endpoint
March 19, 2021 4:56 AM EDTIdera Pharma (NASDAQ: IDRA) March call option implied volatility is at 450, April is at 260; compared to its 52-week range of 99 to 620 into announces ILLUMINATE-301 trial misses primary endpoint. Call put ratio 1 call to 2.2 puts.
... MoreBarclays Downgrades Idera Pharmaceuticals (IDRA) to Equalweight
March 19, 2021 2:08 AM EDTBarclays analyst Gena Wang downgraded Idera Pharmaceuticals (NASDAQ: IDRA) from Overweight to Equalweight with a price target of $2.00.
For an analyst ratings summary and ratings history on Idera Pharmaceuticals click here. For more ratings news on Idera Pharmaceuticals click here.
Shares of Idera Pharmaceuticals closed at $5.21 yesterday.
... MoreJMP Securities Downgrades Idera Pharmaceuticals (IDRA) to Market Perform
March 19, 2021 1:54 AM EDTJMP Securities analyst Reni Benjamin downgraded Idera Pharmaceuticals (NASDAQ: IDRA) from Market Outperform to Market Perform.
For an analyst ratings summary and ratings history on Idera Pharmaceuticals click here. For more ratings news on Idera Pharmaceuticals click here.
Shares of Idera Pharmaceuticals closed at $5.21 yesterday.
... MoreIdera Pharma (IDRA) ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma Did Not Meet Its Primary Endpoint
March 18, 2021 4:16 PM EDTIdera Pharmaceuticals, Inc. (Nasdaq: IDRA; the Company) today is announcing that ILLUMINATE-301, the Companys pivotal registration trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with anti-PD-1 refractory advanced melanoma, did not meet its primary endpoint of objective response rate (ORR). Idera is evaluating its next steps regarding continuation of the trial toward its overall survival (OS) endpoint, which includes evaluating the full data set when it is available. The Company also plans to continue its ILLUMINATE-206 Phase 2 study of tilsotolimod in combination with ipilimumab and nivolumab in patients with microsatellite stable colorectal cancer (MSS-CRC).
... More
Idera Pharma (IDRA) Halted, News Pending
March 18, 2021 4:11 PM EDTIdera Pharma (NASDAQ: IDRA) Halted, News Pending
... More
